Iron therapy in anaemic adults without chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 12, 2014, Pages

  Gurusamy, Kurinchi Selvan ^a   Nagendran, Myura ^a   Broadhurst, Jack F ^b   Anker, Stefan D ^c   Richards, Toby ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; IRON DERIVATIVE;

ADVERSE EVENT; ALLERGIC REACTION; ANEMIA; BLOOD TRANSFUSION; BLOOD VOLUME; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG FATALITY; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; META ANALYSIS; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; ADULT; ANEMIA, IRON-DEFICIENCY; BLOOD; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTILIZATION;

ADMINISTRATION, ORAL; ADULT; ANEMIA; ANEMIA, IRON-DEFICIENCY; BLOOD TRANSFUSION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; IRON; IRON COMPOUNDS; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84925221906     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010640.pub2     Document Type: Review

References (242)

1. Abrahamsen AF. The effect of orally and parenterally administered iron in posthaemorrhagic anaemia. Acta Medica Scandinavica 1965;177(4):503-7.
2. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose assessment in patients with Iron deficiency and chronic heart failure with and without anemia (FAIR-HF): a randomized, double-blind, placebo-controlled, international multi-center phase III study. Circulation 2010;120(21):2156.
3. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine 2009;361(25):2436-48.
4. Comin-Colet J, Lainscak M, Dickstein K, Filippatos G, Johnson P, Luscher TF, et al. Influence of intravenous ferric carboxymaltose on health-related quality of life measures in patients with chronic heart failure and iron deficiency: an analysis from the FAIR-HF study. European Journal of Heart Failure Supplements 2010;9:S120.
5. Comin-Colet J, Lainscak M, Dickstein K, Filippatos G, Johnson P, Luscher TF, et al. Intravenous ferric carboxymaltose improves health-related quality of life in patients with chronic heart failure and iron deficiency irrespective of renal function and anaemia status: an analysis from the FAIR-HF study. NDT Plus 2010;3(3 Suppl 3):iii217.
6. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. European Heart Journal 2012; Vol. Epub ahead of print.
7. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. European Heart Journal 2013;34(1):30-8.
8. Filippatos G, Farmakis D, Colet JC, Dickstein K, Luscher TF, Willenheimer R, et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European Journal of Heart Failure 2013; Vol. Epub ahead of print.
9. Van Craenenbroeck EM, Conraads VM, Greenlaw N, Gaudesius G, Mori C, Ponikowski P, et al. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. European Journal of Heart Failure 2013;15(7):756-62.
10. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Cam L, et al. Darbepoetin alfa (DA) 500MCG or 300MCG once every three weeks (Q3W) with or without iron in patients (PTS) with chemotherapy-induced anemia (CIA). Annals of Oncology 2008;19(S8):viii3.
11. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, et al. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. American Journal of Hematology 2010;85(9):655-63.
12. Altintas S, Bastit L, Vandebroek A, Mossman T, Suto T. Analysis of quality of life responses by efficacy response status in cancer patients with chemotherapy-induced anaemia who received darbopoetin alfa 500 mcg every 3 weeks and IV iron [abstract]. Haematologica 2007;97(Suppl 1):286-7.
13. Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Journal of Clinical Oncology 2008;26(10):1611-8.
14. Lerchenmueller C, Husseini F, Gaede B, Mossman T, Suto T, Vanderbroek A. Intravenous (IV) iron supplementation in patients with chemotherapy-induced anemia (CIA) receiving darbepoetin alfa every 3 weeks (Q3W): iron parameters in a randomized controlled trial. Blood 2006;108(11):Abstract 1552.
15. Pinter T, Mossman T, Suto T, Vansteenkiste J. Effects of intravenous (IV) iron supplementation on responses to every-3-week (Q3W) darbepoetin alfa (DA) by baseline hemoglobin in patients (pts) with chemotherapy-induced anemia (CIA) [abstract]. Journal of Clinical Oncology 2007;25(18S Part I):519.
16. Vandebroek A, Altintas S, Gaede B, Smith K, Yao B, Schupp M. Darbepoetin alfa administered every 3 weeks with or without parenteral iron in anaemic patients with nonmyeloid malignancies receiving chemotherapy: interim results from a randomised open-label study. Haematologica 2006;91(Suppl 1):12.
17. Vandebroek A, Gaede B, Altintas S, Smith K, Yao B, Schupp M, et al. A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy. Journal of Clinical Oncology 2006;24(18S Part I):496.
18. Vandebroek A, Gaede B, Altintas S, Smith K, Yao B, Schupp M, et al. A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy. Journal of Supportive Oncology 2007;5(4 Suppl 2):24-6.
19. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. International Journal of Cardiology 2013; Vol. Epub ahead of print.
20. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. Journal of Cardiac Failure 2007;13(1):14-7.
21. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecologic Oncology 2010;116(3):522-5.
22. Edwards TJ, Noble EJ, Durran A, Mellor N, Hosie KB. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. The British Journal of Surgery 2009;96(10):1122-8.
23. Noble E, Edwards T, Durran A, Mellor N, Hosie KB. A prospective blinded placebo controlled randomised trial of intravenous iron supplementation in patients undergoing colorectal cancer surgery. Colorectal Disease 2009;11(Suppl S1):31.
24. Evstatiev R, Marteau P, Iqbal T, Khalif I, Gudehus M, Gasche C. Intravenously administered ferric carboxymaltose and iron sucrose significantly improve quality of life in patients with IBD-associated iron deficiency anaemia. Journal of Crohn's and Colitis 2011;5(1):S91.
25. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141(3):846-53 e1-2.
26. Iqbal T, Evstatiev R, Chopey K, Harjunpaa J, Gasche C. Significant benefit of ferric carboxymaltose in IBD-associated iron deficiency anaemia is independent of patient baseline characteristics. Journal of Crohn's and Colitis 2011;5(1):S96-7.
27. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21(4):627-32.
28. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. Erratum: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study (Leukemia (2007) vol 21 (627-32) 10.1038/sj.leu.2404562). Leukemia 2008;22(2):462.
29. Hedenus M, Birgegard G, Näsman P, Ahlberg L, Karlsson T, Lauri B, et al. Adjuvant intravenous iron therapy potentiates epoetin beta treatment in anemic, non iron-depleted patients with lymphoproliferative disorders: results of the NIFE study. Hematologica 2006;91(Suppl 1):365.
30. Hetzel D, Strauss W, Bernard K, Li J, Allen L. IV iron treatment of iron deficiency anaemia with ferumoxytol in patients with gastrointestinal disorders unable to take oral iron: a randomized controlled trial versus iron sucrose. Journal of Crohn's and Colitis 2013;7(Suppl 1):S204.
31. Hetzel D, Urboniene A, Bernard K, Strauss W, Cressman M, Li Z, et al. Potential new treatment option for iron deficiency anemia patients with a history of unsatisfactory oral iron therapy: results of a phase III, randomized, open-label, active-controlled trial of ferumoxytol. Blood 2012;120(21):2009.
32. Karkouti K, McCluskey SA, Ghannam M, Salpeter MJ, Quirt I, Yau TM. Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia. Canadian Journal of Anaesthesia 2006;53(1):11-9.
33. Lidder PG, Hosie KB, Marsden M. A double blind prospective randomized controlled trial of iron supplementation in anaemic patients scheduled for colorectal cancer surgery. Colorectal Disease 2004;6(Suppl 1):52-3.
34. Lidder PG, Sanders G, Whitehead E, Douie WJ, Mellor N, Lewis SJ, et al. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery: a prospective, randomised, controlled trial. Annals of the Royal College of Surgeons of England 2007;89(4):418-21.
35. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Granno C, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scandanavian Journal of Gastroenterology 2009;44(7):838-45.
36. Maccio A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation associated with rHuEPObeta for the treatment of anemia in advanced cancer patients submitted to chemotherapy. Journal of Clinical Oncology 2010;28(15 Suppl 1):2010.
37. Maccio A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist 2010;15(8):894-902.
38. Madi-Jebara SN, Sleilaty GS, Achouh PE, Yazigi AG, Haddad FA, Hayek GM, et al. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia 2004;18(1):59-63.
39. Parker MJ. Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. The Journal of Bone and Joint Surgery. American Volume 2010;92(2):265-9.
40. Pieracci FM, Henderson P, Rodney JR, Holena DN, Genisca A, Ip I, et al. Randomized, double-blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. Surgical Infections 2009;10(1):9-19.
41. Steensma DP, Dakhil SR, Dalton R, Kahanic SP, Kugler JW, Stella PJ, et al. A phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia: a study of the Mayo Clinic Cancer Research Consortium (MCCRC). Blood 2009;114(22):Abstract 630.
42. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. Journal of Clinical Oncology 2010;29(1):97-105.
43. Sutton PM, Cresswell T, Livesey JP, Speed K, Bagga T. Treatment of anaemia after joint replacement: a double-blind, randomised, controlled trial of ferrous sulphate versus placebo. The Journal of Bone and Joint Surgery. British Volume 2004;86(1):31-3.
44. Dickerhoof R, DeBusk K, Bernard K, Strauss W, Allen LF, Acaster S. Measuring fatigue in iron deficiency anemia patients: a psychometric validation study. Value in Health 2013;16(3):A36.
45. Raj SV, Cressman M, Ford D, Strauss W, Poss G, Bernard K, et al. Ferumoxytol treatment results in robust hemoglobin increases in iron deficiency anemia patients with a history of unsatisfactory oral iron therapy in a phase III, randomized, placebo-controlled trial. Blood 2012;120(21):2098.
46. Raj SV, Hsieh A, Strauss W, Stevenson M, Bernard K, Allen LF. Ferumoxytol treatment demonstrates significant improvements in fatigue and health-related quality of life in iron deficiency anemia patients with a history of unsatisfactory oral iron therapy. Blood 2012;120(21):478.
47. Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, et al. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. American Journal of Hematology 2013; Vol. Epub ahead of print.
48. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009;49(12):2719-28.
49. Anker SD, Okonko DO, Grzeslo A, Witkowski T, Missouris CG, Banasiak W, et al. Intravenous iron sucrose in anemic and non-anemic iron deficient patients with CHF: a randomized, controlled, observer-blinded intervention study (FERRIC-HF). Journal of Cardiac Failure 2006;12(8):S179.
50. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Rationale and design of Ferinject((R)) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure 2009;11(11):1084-91.
51. Anonymous. The therapeutic effectiveness of various compounds containing iron. Nutrition Reviews 1966;24(8):232-5.
52. Aronstam A, Aston DL. A comparative trial of a controlled-release iron tablet preparation ('Ferrocontin' Continus) and ferrous fumarate tablets. Pharmatherapeutica 1982;3(4):263-7.
53. Auerbach M, Henry DH. Increased importance of intravenous iron in chemotherapy-induced anemia. Journal of Clinical Oncology 2007;25(15):2145-6.
54. Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. American Journal of Hematology 2011;86(10):860-2.
55. Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia 2012;2012:172104.
56. Barrison IG, Roberts PD, Kane SP. Oral or parenteral iron treatment in chronic ulcerative colitis?. British Medical Journal 1981;282(6275):1514.
57. Beris P, Verholen F, Sadowski M, Noger M, Hoffmeyer P. Correction of anemia of the post-operative period after orthopedic surgery by oral versus intravenous iron versus intravenous iron epo: a prospective randomized trial. Haematologica 2006;91(Suppl 1):6.
58. Bermejo San Jose F. [Is intravenous iron really useful in inflammatory bowel disease? Would oral iron not be simpler and cheaper?]. Gastroenterologia y Hepatologia 2009;32(1):63-4.
59. Bernabeu-Wittel M, Aparicio R, Romero M, Murcia-Zaragoza J, Monte-Secades R, Rosso C, et al. Ferric carboxymaltose with or without erythropoietin for the prevention of red-cell transfusions in the perioperative period of osteoporotic hip fractures: a randomized controlled trial. The PAHFRAC-01 project. BMC Musculoskeletal Disorders 2012;13:27 (1 to 8).
60. Bisbe E, Garcia-Erce JA, Diez-Lobo AI, Munoz M. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. British Journal of Anaesthesia 2011;107(3):477-8.
61. Black GS. A comparison of two iron tablet preparations in the treatment of iron deficiency anaemia. Journal of International Medical Research 1981;9(4):295-6.
62. Bulvik S, Karalnick S, Leibovitz G, Benist A, Niven M. Intravenous iron gluconate or iron saccharate for patients with iron deficiency anemia with malabsorption or oral iron intolerance. Blood 1997;90(10 Suppl 1 Pt 2):11b.
63. Crosby L, Palarski VA, Cottington E, Cmolik B. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: a randomized, placebo-controlled study. Heart & Lung 1994;23(6):493-9.
64. Cuenca J, Garcia-Erce JA, Munoz M. Efficacy of intravenous iron sucrose administration for correcting preoperative anemia in patients scheduled for major orthopedic surgery. Anesthesiology 2008;109(1):151-2.
65. Desai HG, Mehta BC, Borkar AV, Jeejeebhoy KN. Effect of intravenous iron therapy on gastric acid secretion in iron-deficiency anaemia. Gut 1968;9(1):91-5.
66. Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine 2009;10(2):206-11.
67. Evers JEM. Iron-poly(sorbitol-gluconic acid) complex and iron-dextran in the treatment of severe iron deficiency anaemia. Scandinavian Journal of Haematology 1977;19(Suppl 32):279-85.
68. Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology 2013;11(3):269-77.
69. Fitzgerald JE, Simpson JA, Acheson AG. The use of intravenous iron in patients with cancer related anaemia: don't overlook iron deficiency anaemia in colorectal cancer. British Journal of Haematology 2008;143(5):754.
70. Froessler B, Papendorf D. Intravenous iron sucrose - an effective and attractive modality for perioperative anaemia management. Anaesthesia and Intensive Care 2010;38(5):960-2.
71. Garrido-Martin P, Nassar-Mansur MI, De La Llana-Ducros R, Virgos-Aller TM, Fortunez PMR, Avalos-Pinto R, et al. The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial. Interactive CardioVascular and Thoracic Surgery 2012;15(6):1013-8.
72. Gasche C, Dejaco C, Waldhor T, Reinisch W, Tillinger W, Vogelsang H, et al.[Double-blind, placebo-controlled study of erythropoietin and iron saccharate in the treatment of anaemia in Crohn's disease]. Zeitschrift fur Gastroenterologie 1995;33(5):320.
73. Gedik Y, Erduran E, Mocan H, Aynaci FM, Okten A. The efficacy of ferrous sulfate and ferric polymaltose in therapy of iron deficiency anemia. Annals of Medical Sciences 1995;4(2):143-4.
74. Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders 2009;24(10):1445-52.
75. Harris S, Tepper D, Ip R. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency-ferric-HF: a randomized, controlled, observer-blinded trial. Congestive Heart Failure 2009;15(4):208.
76. Hussain I, Bhoyroo J, Butcher A, Koch TA, He A, Bregman DB. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia 2013;2013:169107.
77. Kaltwasser JP, Ockelmann R, Schalk KP. Oral iron therapy: preparations with rapid or delayed iron liberation?. Medizinische Klinik 1987;82(21):730-5.
78. Kaltwasser JP, Schwarz-Van DSW. Oral iron treatment: bioavailability and therapeutic efficacy of ferrous iron as effervescent tablets in posthaemorrhagic iron-deficiency anaemia. Deutsche Medizinische Wochenschrift 1989;114(31-32):1188-95.
79. Kulnigg S, Teischinger L, Dejaco C, Waldhor T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. American Journal of Gastroenterology 2009;104(6):1460-7.
80. Kulnigg-Dabsch S, Evstatiev R, Dejaco C, Gasche C. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS ONE 2012;7(4):e34520.
81. Lewinski U, van der Lijn E, Djaldetti M. [Intravenous iron-dextran versus peroral iron and blood transfusion for anemia]. Harefuah 1973;85(4):167-9.
82. Liguori L. Iron protein succinylate in the treatment of iron deficiency: controlled, double-blind, multicenter clinical trial on over 1, 000 patients. International journal of Clinical Pharmacology, Therapy, and Toxicology 1993;31(3):103-23.
83. Lipsic E, van der Meer P. Erythropoietin, iron, or both in heart failure: FAIR-HF in perspective. European Journal of Heart Failure 2010;12(2):104-5.
84. Littlewood TJ. Intravenous or oral iron?. American Journal of Hematology 2012;87(2):134-5.
85. Liu TC, Lin SF, Chang CS, Yang WC, Chen TP. Comparison of a combination ferrous fumarate product and a polysaccharide iron complex as oral treatments of iron deficiency anemia: a Taiwanese study. International Journal of Hematology 2004;80(5):416-20.
86. Mundy GM, Birtwistle SJ, Power RA. The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty. The Journal of Bone and Joint Surgery. British Volume 2005;87(2):213-7.
87. Munoz M, Naveira E, Seara J, Cordero J, Marcos F, Bisbe E. Postoperative intravenous iron after lower limb arthroplasty: a comparative study of different doses on transfusion requirements. European Journal of Anaesthesiology 2011;28:90.
88. Munoz M, Naveira E, Seara J, Cordero J, Martos F. Postoperative iron after lower limb arthroplasty: a comparative study of the effects of 300 vs. 600 mg IV iron administration on transfusion requirements. Transfusion Alternatives in Transfusion Medicine 2011;12(1):34-5.
89. Munoz M, Naveira E, Seara J, Cordero J. Effects of postoperative intravenous iron on transfusion requirements after lower limb arthroplasty. British Journal of Anaesthesia 2012;108(3):532-4.
90. Murgel GA. Therapy of hypochromic anemia using ferrous sulfate (comparative study of reinforced sustained-release pills and conventional pills). Revista Brasileira de Medicina 1969;26(6):375-9.
91. Najean Y, Acuto G, Scotti A. Multicentre double-blind clinical trial of iron protein succinylate in comparison with iron sulfate in the treatment of iron deficiency anaemia. Clinical Drug Investigation 1995;10(4):198-207.
92. Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. American Journal of Hematology 2013;88(2):97-101.
93. Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2013; Vol. Epub ahead of print.
94. Ravanbod M, Asadipooya K, Kalantarhormozi M, Nabipour I, Omrani GR. Treatment of iron-deficiency anemia in patients with subclinical hypothyroidism. American Journal of Medicine 2013;126(5):420-4.
95. Raya J, Garrido P, Pecos P, Martinez R, Nassar I, De La Llana R, et al. Analysis of two different schemes of iron treatment to improve postoperative anemia in cardiac surgery: a randomized double-disguised, triple-blind study. Haematologica 2010;95(Suppl 2):706.
96. Rondinelli MB, Inghilleri G, Pavesi M, Di Bartolomei A, Pagnotta R, Terlizzi F, et al. Efficacy of ferrous bisglycinate for the management of patient undergoing pre-operative blood donation or with pre-operative anaemia in orthopedic surgery: a prospective study. Transfusion Medicine 2013;23(s1):36.
97. Schatz U, Arneth B, Siegert G, Siegels D, Fischer S, Julius U, et al. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations. Atherosclerosis Supplements 2013;14(1):115-22.
98. Serrano-Trenas JA, Ugalde PF, Cabello LM, Chofles LC, Lazaro PS, Benitez PC. Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. Transfusion 2011;51(1):97-104.
99. Singh A, Hertel J, Bernardo M, Baptista J, Kausz A, Brenner L, et al. A double-blind, placebo-controlled, randomized phase III study of the safety of ferumoxytol as a new intravenous iron replacement therapy. American Journal of Kidney Diseases 2007;49(4):A32.
100. Strauss W, Bernard K, Li Z, Allen L. Safety and efficacy of ferumoxytol vs. iron sucrose in the treatment of iron deficiency anemia (IDA) in patients with normal and abnormal renal function. Nephrology Dialysis Transplantation 2013;28(Suppl 1):i9.
101. Wang L, Li G, Liao C, Wang F. The effects of oral vs venous iron supplement in treatment of iron deficiency of maintained patients with anemia [Abstract No. PUB324]. Journal of the American Society of Nephrology 2003;14(Suppl S):842a.
102. Weatherall M, Maling TJ. Oral iron therapy for anaemia after orthopaedic surgery: randomized clinical trial. ANZ Journal of Surgery 2004;74(12):1049-51.
103. Zauber NP, Zauber AG, Gordon FJ, Tillis AC, Leeds HC, Berman E, et al. Iron supplementation after femoral head replacement for patients with normal iron stores. JAMA 1992;267(4):525-7.
104. Adsul BB, Desai A, Gawde A, Baliga V. Comparative assessment of the bioavailability, efficacy and safety of a modified-release (MR) carbonyl iron tablet and oral conventional iron preparation in adult Indian patients with nutritional iron deficiency anaemia. Journal of the Indian Medical Association 2005;103(6):338-42.
105. Anthony LB, Gabrail NY, Ghazal H, Woytowitz DV, Flam MS, Drelichman A, et al. IV iron sucrose for cancer and/or chemotherapy-induced anemia in patients treated with erythropoiesis stimulating agents. Community Oncology 2011;8(6):270-8.
106. Bellet RE, Ghazal H, Flam M, Drelichman A, Gabrail N, Woytowitz D, et al. A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy [Abstract No. 9109]. Journal of Clinical Oncology 2007;25(18S Part I):519.
107. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. Journal of Clinical Oncology 2004;22(7):1301-7.
108. Auerbach M, Barker L, Bahrain H, Trout R, McIlwain M, Ballard H. Intravenous iron (IV Fe) optimizes the response to erythropoietin (EPO) in patients with anemia of cancer and cancer chemotherapy: results of a multicenter, open-label, randomized trial. Blood 2001;98(11):799A.
109. Ballard H, Rana J, Ackerman A, Merino R, RosenoffS, Kastritsis C, et al. Total dose infusion (TDI) of iron dextran (ID) optimizes erythropoietin (EPO) responsiveness in the anemia of cancer (CA) [abstract]. Proceedings of the American Society of Clinical Oncology 1999;18:581a.
110. Bisbe E. Intravenous iron to treat post-operative anaemia. Transfusion Medicine 2013;23(s1):13-4.
111. Bisbe E. Intravenous iron to treat postoperative anaemia. Vox Sanguinis 2013;105(Suppl 1):50.
112. Bisbe E, Molto L, Arroyo R, Santiveri X, Munoz M. The efficacy of intravenous iron for treating postoperative anemia and hastening functional recovery in patients undergoing total knee arthroplasty: preliminary results from a randomized controlled trial. Transfusion Alternatives in Transfusion Medicine 2012;12(2):29-30.
113. Chen BB, Lin GW, Wu W, Chen Y, Wang JE, Wang YL. Comparitive study on three iron preparations for treatment of iron deficiency anemia: a randomized-controlled trial. Shanghai Medical Journal 2002;25(3):154-7.
114. Devasthali SD, Gordeuk VR, Brittenham GM, Bravo JR, Hughes MA, Keating LJ. Bioavailability of carbonyl iron: a randomized, double-blind study. European Journal of Haematology 1991;46(5):272-8.
115. Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2005;22(9):831-8.
116. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2005;40(9):1058-65.
117. Ferrari P, Nicolini A, Manca ML, Rossi G, Anselmi L, Conte M, et al. Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedicine and Pharmacotherapy 2012; Vol. Epub ahead of print.
118. Giordano G, Mondello P, Tambaro R, De Maria M, D'Amico F, Sticca G, et al. Intravenous iron support vs oral liposomal iron support in patients with refractory anemia treated with Epo alpha. Monocentric prospective study. Leukemia Research 2011;35:S137.
119. Gordeuk VR, Brittenham GM, Hughes M, Keating LJ, Opplt JJ. High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial. The American Journal of Clinical Nutrition 1987;46(6):1029-34.
120. Henry DH, Dahl NV. Does quality of life improvement precede anemia correction in patients with chemotherapy-induced anemia treated with intravenous iron? [abstract]. Journal of Clinical Oncology 2007;25(18S Part I):513.
121. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy: results of a multicenter, randomized trial. Blood 2004;104(11 Part 2):10b.
122. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12(2):231-42.
123. Izuel-Rami M, Garcia-Erce JA, Cuenca J, Gomez-Barrera M, Villar I, Rabanaque MJ. Recovery from postoperative anaemia after hip fracture replacement surgery. Is there a role for erythropoietin and intravenous iron?. Transfusion Alternatives in Transfusion Medicine 2006;8(1 Suppl):81.
124. Jacobs P, Wood L, Bird AR. Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology 2000;5(1):77-83.
125. Jakobsen D, Wiesenthal M, Hartmann F, Dignass A, Weber-Mangal S, Stein J. Safety and efficacy of bolus administered ferric carboxymaltose (500 mg) in the treatment of iron deficiency anaemia in IBD patients. Journal of Crohn's and Colitis 2013;7(Suppl 1):S162.
126. Kanakaraddi VP, Hoskatti CG, Nadig VS, Patil CK, Maiya M. Comparative therapeutic study of T.D.I. and I.M. injections of iron dextran complex in anaemia. Journal of Association of Physicians of India 1973;21(10):849-53.
127. Kang SB, Kim SC, Kim YT. Phase IV randomized study on safety and usefulness of parenteral iron (iron sucrose, venoferrum C) in the management of preoperative anemia in patients with menorrhagia: preliminary data. XVIII FIGO World Congress of Gynecology and Obstetrics 2006;2:89.
128. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecologic Oncology 2007;105(1):199-204.
129. Kim YH, Chung HH, Kang SB, Kim SC, Kim YT. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematologica 2009;121(1):37-41.
130. Kulnigg S, Rumyantsev V, Stoinov S, Simanenkov V, Levchenko E, Karnafel W, et al. A novel intravenous iron formulation for treatment of anemia in IBD: the Ferinject randomized, controlled trial. Gastroenterology 2007;132(4 Suppl 2):A501-2.
131. Kulnigg S, Rumyantsev V, Stoinov S, Simanenkov V, Levchenko E, Karnafel W, et al. A novel intravenous iron formulation for treatment of anemia in IBD: the Ferinject randomized, controlled trial. Zeitschrift fur Gastroenterologie 2007;44(A2):645-6.
132. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. American Journal of Gastroenterology 2008;103(5):1182-92.
133. LangstaffRJ, Geisser P, Heil WG, Bowdler JM. Treatment of iron-deficiency anaemia: a lower incidence of adverse effects with Ferrum Hausmann than ferrous sulphate. British Journal of Clinical Research 1993;4:191-8.
134. Li XX, Chen XL, Zhang MH, Wang YH, Da WM, Li JY. [A randomized controlled and multicenter clinical study of ferrous L-threonate in treatment of iron deficiency anemia]. Zhonghua Nei Ke Aa Zhi [Chinese Journal of Internal Medicine] 2005;44(11):844-7.
135. Michalopoulou H, Vaitsis J, Massias S, Stamatis P. Effect of correction of anemia in severe congestive heart failure. Critical Care 2009;13:S168.
136. Mimura EC, Bregano JW, Dichi JB, Gregorio EP, Dichi I. Comparison of ferrous sulfate and ferrous glycinate chelate for the treatment of iron deficiency anemia in gastrectomized patients. Nutrition 2008;24(7-8):663-8.
137. Marti PP. Iron therapy in colo-rectal neoplasm and iron deficiency anemia: intravenous iron sucrose versus oral ferrous sulphate. http://ClinicalTrials.gov/show/NCT00199277 2005:Accessed November 2014.
138. Trokars M. Intravenous (IV) iron vs. no iron as the treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin therapy. http://ClinicalTrials.gov/show/NCT00236951 2010:Accessed November 2014.
139. Agrawal SG. Epoetin alfa or epoetin beta with or without iron infusion in treating anemia in patients with cancer. http://ClinicalTrials.gov/show/NCT00482716 2009:Accessed November 2014.
140. Tokars M. Safety and tolerability of ferric carboxymaltose (FCM) versus iron dextran in treating iron deficiency anemia. http://ClinicalTrials.gov/show/NCT00704028 2011:Accessed November 2014.
141. ®) with or without erythropoietin in patients undergoing orthopaedic surgery. http://ClinicalTrials.gov/show/NCT00706667 2013:Accessed November 2014.
142. Gasche C. Ferinject for correction of anaemia in IBD patients, FER-IBD-COR. http://ClinicalTrials.gov/show/NCT00810030 2012:Accessed November 2014.
143. Vilstrup H. Iron substitution after upper gastro-intestinal bleeding. http://ClinicalTrials.gov/show/NCT00978575 2013:Accessed November 2014.
144. Tokars M. Efficacy and safety of intravenous ferric carboxymaltose (FCM) in patients with iron deficiency anemia (IDA). http://ClinicalTrials.gov/show/NCT00982007 2013:Accessed November 2014.
145. Pharmacosmos A/S. Iron oligosaccharide in inflammatory bowel disease subjects with iron deficiency anaemia. http://ClinicalTrials.gov/show/NCT01017614 2012:Accessed November 2014.
146. Eirini K, Cushway T. Ferric carboxymaltose for treatment of anaemia of cancer in subjects with multiple myeloma receiving chemotherapy. http://ClinicalTrials.gov/show/NCT01100879 2011:Accessed November 2014.
147. Karlsson T, McNamara M. Ferric carboxymaltose in subjects with functional iron deficiency undergoing chemotherapy. http://ClinicalTrials.gov/show/NCT01101399 2012:Accessed November 2014.
148. AMAG Pharmaceuticals, Inc. A trial of ferumoxytol for the treatment of iron deficiency anemia. http://ClinicalTrials.gov/show/NCT01114139 2013:Accessed November 2014.
149. AMAG Pharmaceuticals, Inc. A trial comparing ferumoxytol with iron sucrose for the treatment of iron deficiency anemia. http://ClinicalTrials.gov/show/NCT01114204 2013:Accessed November 2014.
150. ®) as monotherapy (without erythropoiesis stimulating agents) in comparison with oral iron sulfate in subjects with non-myeloid malignancies associated with chemotherapy induced anaemia (CIA). http://ClinicalTrials.gov/show/NCT01145638. Accessed November 2014.
151. GSK Clinical Trials. A study to demonstrate the efficacy and tolerability of ferrous bisglycinate chelate in iron deficiency anaemia and to compare these with those of ferrous ascorbate. http://ClinicalTrials.gov/show/NCT01160198 2012:Accessed November 2014.
152. Pieracci FM, Moore EE. IV iron for the anemia of traumatic critical illness. http://ClinicalTrials.gov/show/NCT01180894 2012:Accessed November 2014.
153. Tocars M. Hypophosphatemia with intravenous ferric carboxymaltose versus iron dextran in women with iron deficiency secondary to heavy uterine bleeding. http://ClinicalTrials.gov/show/NCT01307007 2013:Accessed November 2014.
154. Price E, Schrier S, Artiz A. Trial to evaluate the efficacy of intravenous iron in older adults with unexplained anemia. http://ClinicalTrials.gov/show/NCT01309659 2012:Accessed November 2014.
155. Harper C, Emery L. Safety and efficacy study of oral ferric iron to treat iron deficiency anaemia in quiescent ulcerative colitis (AEGIS-1). http://ClinicalTrials.gov/show/NCT01340872 2011:Accessed November 2014.
156. Harper C, Emery L. Safety and efficacy study of oral ferric iron to treat iron deficiency anaemia in quiescent Crohn's disease (AEGIS-2). http://ClinicalTrials.gov/show/NCT01352221 2011:Accessed November 2014.
157. UCB, Inc. A double-blind, double-dummy, parallel, active-controlled, randomized and multi-center trial to investigate efficacy and safety in subjects with iron deficiency anemia for ferrous (II) glycine sulphate complex versus polyferose capsules therapy. http://ClinicalTrials.gov/show/NCT01425463 2013:Accessed November 2014.
158. Savoye G, Colombel JF. Comparison of ferrisat vs placebo in anemia associated to inflammatory bowel disease during anti-TNF therapy. http://ClinicalTrials.gov/show/NCT01428843 2012:Accessed November 2014.
159. Blot J. Efficacy of parenteral iron supplementation after gastrointestinal bleeding in subjects over 65. http://ClinicalTrials.gov/show/NCT01690585 2013:Accessed November 2014.
160. Keeler B, Ahceson AG. IVICA: intravenous iron in colorectal cancer associated anaemia. http://ClinicalTrials.gov/show/NCT01701310 2013:Accessed November 2014.
161. ® assessment in gastrectomy patients with acute isovolemic anemia (FAIRY). http://ClinicalTrials.gov/show/NCT01725789 2013:Accessed November 2014.
162. Chae SW. Efficacy and safety of heme-iron polypeptide on improvement of anemia. http://ClinicalTrials.gov/show/NCT01733979 2012:Accessed November 2014.
163. Karakas M. Iron in congestive heart failure. http://ClinicalTrials.gov/show/NCT01837082 2013:Accessed November 2014.
164. Montano-Pedroso JC. Iron supplementation for acute anemia after postbariatric abdominoplasty. http://ClinicalTrials.gov/show/NCT01857011 2013:Accessed November 2014.
165. Keeler B, Acheson AG. Iron replacement in oesophagogastric neoplasia. http://ClinicalTrials.gov/show/NCT01927328 2013:Accessed November 2014.
166. Koch T, Trokars M. Trial to evaluate the utility of serum hepcidin levels to predict response to oral or iv iron and to compare safety, effect on quality of life, and resource utilization of injectafer vs. intravenous standard of care for the treatment of iron deficiency anemia (IDA) in an infusion center setting. http://ClinicalTrials.gov/show/NCT01950247 2013:Accessed November 2014.
167. Okonko D, Greszlo A, Witkowski T, Mandal A, Slater R, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anaemic and nonanaemic patients with symptomatic chronic heart failure and iron deficiency (ferric-HF): a randomised, controlled, observer-blinded trial. Heart 2007;93(Suppl 1):A41.
168. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Foldes G, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and non-anemic patients with symptomatic chronic heart failure and iron deficiency: a randomised, controlled, observer-blinded trial (FERRIC-HF). Circulation 2006;114(18 Suppl S):407.
169. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. Journal of the American College of Cardiology 2008;51(2):103-12.
170. Okonko DO, Grzeslo A, Witkowski T, Missouris CG, Banasiak W, Poole-Wilson PA, et al. Effect of intravenous iron sucrose on exercise tolerance in anaemic and non-anaemic iron deficient patients with chronic heart failure: a randomised, controlled, observer-blinded trial (FERRIC-HF). European Heart Journal 2006;27(Suppl 1):167.
171. Olijhoek G, Megens JGN, Musto P, Nogarin L, Gassmann-Mayer C, Vercammen E, et al. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 2001;41(7):957-63.
172. Oliver A, Sierra P, Noe L, Monllau V, Ortiz JC. Efficacy of post-operative intravenous iron in elective major urological surgery. Transfusion Alternatives in Transfusion Medicine 2010;11(Suppl S2):33.
173. Pedrazzoli P, Scotti A, Farina D. Comparison trial of iron succinylprotein complex or iron gluconate complex in the treatment of iron deficiency anemia. Clinical Therapeutics 1988;10(4):414-20.
174. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. Journal of Clinical Oncology 2008;26(10):1619-25.
175. Siena S, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. Annals of Oncology 2007;18(Suppl 11):87-8.
176. Prasad N, Rajamani V, Hullin D, Murray JM. Post-operative anaemia in femoral neck fracture patients: does it need treatment? A single blinded prospective randomised controlled trial. Injury 2009;40(10):1073-6.
177. Prassler R, Deppe H, Huchzermeyer H. Value of iron supplementation in gastrointestinal bleeding. Leber Magen Darm 1998;28(1):21-3.
178. Roe PF. The effect of varying concentrations of intravenous iron dextran (Imferon) on the complication rate. East African Medical Journal 1968;45(11):713-9.
179. Schroder O, Mickisch O, Seidler U, De Weerth A, Dignass AU, Herfarth H, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a randomized, controlled, open-label, multicenter study. American Journal of Gastroenterology 2005;100(11):2503-9.
180. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, et al. A randomised multi-centre study on the application of intravenous iron sucrose versus oral iron sulphate in the therapy of iron deficient anaemia in patients with chronic irritable bowel disease. Zeitschrift fur Gastroenterologie 2005;43(8):915.
181. Seid MH, Mangione A, Valaoras TG, Anthony LB, Barish CF. Safety profile of iron carboxymaltose, a new high dose intravenous iron in patients with iron deficiency anemia. Blood 2006;108(11 Part 2):8.
182. Velhal GD, Bichile SK, Pai NP, Tilwe S. Effectivness of oral versus parenteral iron therapy study conducted at urban health centre. Indian Journal of Community Medicine 1991;16(4):157-60.
183. Richards T. Preoperative intravenous iron to treat anaemia in major surgery. http://ClinicalTrials.gov/show/NCT01692418 2012.
184. Albaramki J, Hodson EM, Craig JC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD007857.pub2]
185. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. American Journal of Health-System Pharmacy 2012;69(4):310-20.
186. Balarajan Y, Ramakrishnan U, Ozaltin E, Shankar AH, Subramanian SV. Anaemia in low-income and middle-income countries. Lancet 2011;378(9809):2123-35.
187. Baribeault D, Auerbach M. Iron replacement therapy in cancer-related anemia. American Journal of Health-System Pharmacy 2011;68(10 Suppl 1):S4-14.
188. Beattie WS, Karkouti K, Wijeysundera DN, Tait G. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology 2009;110(3):574-81.
189. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. Journal of the American Society of Nephrology 2004;15(Suppl 2):S93-8.
190. Davis SL, Littlewood TJ. The investigation and treatment of secondary anaemia. Blood Reviews 2012;26(2):65-71.
191. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
192. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
193. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
194. Dodd JM, Dare MR, Middleton P. Treatment for women with postpartum iron deficiency anaemia. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004222.pub2]
195. Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. Journal of Surgical Research 2002;102(2):237-44.
196. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed) 1997;315(7109):629-34.
197. Fireman Z, Kopelman Y. The role of video capsule endoscopy in the evaluation of iron deficiency anaemia. Digestive and Liver Disease 2004;36(2):97-102.
198. Foubert J. Cancer-related anaemia and fatigue: assessment and treatment. Nursing Standard 2006;20(36):50-7.
199. Ghali JK. Anemia and heart failure. Current Opinion in Cardiology 2009;24(2):172-8.
200. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut 2011 May 11 [Epub ahead of print].
201. Goonewardene M, Shehata M, Hamad A. Anaemia in pregnancy. Best Practice & Research. Clinical Obstetrics & Gynaecology 2012;26(1):3-24.
202. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. The British Journal of Surgery 2009;96(4):342-9.
203. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
204. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Colloboration, 2011. www.cochrane-handbook.org.
205. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
206. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
207. Hyder SM, Persson LA, Chowdhury AM, Ekstrom EC. Do side-effects reduce compliance to iron supplementation? A study of daily- and weekly-dose regimens in pregnancy. Journal of Health, Population, and Nutrition 2002;20(2):175-9.
208. International Conference on Harmonisation of Technical Requiements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulation & ICH Guidelines. Media: Parexel Barnett, 1996.
209. Jain N, Jain VM. Prevalence of anemia in school children. Medical Practice and Review 2012;3(1):1-4.
210. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
211. Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohn's Colitis 2012;6(3):267-75.
212. Leichtle SW, Mouawad NJ, Lampman R, Singal B, Cleary RK. Does preoperative anemia adversely affect colon and rectal surgery outcomes?. Journal of the American College of Surgeons 2011;212(2):187-94.
213. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ (Clinical Research ed) 2013;347:f4822.
214. Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. European Journal of Gastroenterology & Hepatology 2012;24(2):109-16.
215. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
216. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
217. McIntyre LA, Tinmouth A, Fergusson D. Intravenous iron therapy for treatment of anaemia. BMJ (Clinical Research ed) 2013;347:f5378.
218. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
219. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, et al. Preoperative anemia and postoperative outcomes in noncardiac surgery. Lancet 2011;378(9800):1396-407.
220. NCBI. Hematocrit. http://www.ncbi.nlm.nih.gov/mesh/68006400 (accessed 19 July 2011).
221. NCBI. Hemoglobins. http://www.ncbi.nlm.nih.gov/mesh/68006454 (accessed 19 July 2011).
222. NCBI. Iron. http://www.ncbi.nlm.nih.gov/mesh/68007501 (accessed 19 July 2011).
223. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
224. U.S. National Library of Medicine. Anemia. http://www.ncbi.nlm.nih.gov/mesh/68000740 (accessed 19 July 2011).
225. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
226. Reveiz L, Gyte GML, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD003094.pub3]
227. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
228. Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. TheScientificWorldJournal 2012;2012:846824.
229. Scholz BD, Gross R, Schultink W, Sastroamidjojo S. Anaemia is associated with reduced productivity of women workers even in less-physically-strenuous tasks. British Journal of Nutrition 1997;77(1):47-57.
230. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
231. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. Higgins JPT, Green S(editors). Cochrane Handbook for Systematic Reviewsof Interventions Version 5.1.0 [updated March 2011].The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
232. Silverstein SB, Rodgers GM. Parenteral iron therapy options. American Journal of Hematology 2004;76(1):74-8.
233. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
234. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
235. von Haehling S, Schefold JC, Hodoscek LM, Doehner W, Mannaa M, Anker SD, et al. Anaemia is an independent predictor of death in patients hospitalized for acute heart failure. Clinical Research in Cardiology 2010;99(2):107-13.
236. Waldmann A, Koschizke JW, Leitzmann C, Hahn A. Dietary iron intake and iron status of German female vegans: results of the German vegan study. Annals of Nutrition & Metabolism 2004;48(2):103-8.
237. Weiss G, Goodnough LT. Anemia of chronic disease. The New England Journal of Medicine 2005;352(10):1011-23.
238. World Health Organization, United Nations University, UNICEF. Iron deficiency anaemia. Assessment, prevention, and control. A guide for managers. http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/NHD_01_13/en/2001:WHO/NHD/01.3 (accessed 19 August 2011).
239. World Health Organization. Worldwide prevalence of anaemia 1993-2005. http://www.who.int/vmnis/publications/anaemia_prevalence/en/index.html. (accessed 19 August 2011).
240. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research ed) 2008;336:601-5.
241. Yadav D, Chandra J. Iron deficiency: beyond anemia. Indian Journal of Pediatrics 2011;78(1):65-72.
242. Zeng X, Wu T. Iron supplementation for iron deficiency anemia in children. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006465]